首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >FORMULATION, CHARACTERISATION AND IN-VITRO EVALUATION OF NOVEL IONICALLY CROSS LINKED CASEIN NANOPARTICLES FOR MEMANTINE HYDRO-CHLORIDE DELIVERY
【24h】

FORMULATION, CHARACTERISATION AND IN-VITRO EVALUATION OF NOVEL IONICALLY CROSS LINKED CASEIN NANOPARTICLES FOR MEMANTINE HYDRO-CHLORIDE DELIVERY

机译:新型离离子交叉连接酪蛋白纳米粒子的制剂,表征和体外评价,用于Memantine水氯化物

获取原文
获取外文期刊封面目录资料

摘要

The objective of the study was to fabricate protein nanoparticles for better controlled and targeting action of drug, which can also overcome the problems like multidose therapy, poor patient compliance and high cost associated with conventional formulations. Memantine HCl loaded casein nanoparticles (F1 to F6) were prepared by ionically cross-linked method. The formulated nanoparticles were evaluated for external morphological characters, determination of particle size analysis, zeta potential, drug content, entrapment efficiency and emin-vitro /emrelease studies. The particle size varied from 148 to 317 nm and zeta potential was in negative and its value found to be – 46.4 mV. The drug content for the Memantine HCl loaded casein nanoparticles varied from 69.5 ± 7.2% to 87.9 ± 1.2%. The entrapment efficiencies were found to be minimum and maximum of 55.50 ± 2.4% and 86.30 ± 3.6%. The percentage yields of all formulations were in the range of 48.24 ± 1.24 to 86.13 ± 1.37%. emIn-vitro/em release of drug follows zero order and showed sustained release behaviour for a period of 24 hr. The optimized formulation contained STTP and casein in 1:3 ratio and could demonstrate the sustained release sucessfully. Memantine HCl loaded casein nanoparticle is a potential new delivery system for treatment of Alzheimer’s disease.
机译:该研究的目的是制造蛋白质纳米颗粒以获得更好的药物靶向和靶向作用,这也可以克服多剂量治疗,患者依从性和与常规配方相关的高成本等问题。通过离子交联的方法制备Memantine HCl负载酪蛋白纳米粒子(F1至F6)。评价配制的纳米颗粒用于外部形态特征,测定粒度分析,Zeta电位,药物含量,夹带效率和在体外释放研究。粒径从148变化到317nm,Zeta电位为阴性,并且其值为46.4 mV。 Memantine HCl的药物含量为酪蛋白纳米颗粒的含量为69.5±7.2%至87.9±1.2%。发现血管效率至少为55.50±2.4%和86.30±3.6%。所有配方的产量为48.24±1.24至86.13±1.37%。 在体外药物释放均遵循零阶,显示出24小时的时间持续释放行为。优化的制剂包含STTP和酪蛋白,1:3的比例,并且可以成功展示持续释放。 Memantine HCl负载酪蛋白纳米粒子是用于治疗阿尔茨海默病的潜在新的递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号